End-of-treatment changes in summary patient-reported outcomes (PROs) from patients'
own baseline levels in patients treated with sofosbuvir (SOF)/velpatasvir and SOF +
ribavirin regardless of duration. P values reflect differences
between the 2 treatment groups. Changes exceeding 2 points were also statistically
significant (P < .05) when compared with zero change (ie, no
change from patient's own baseline PRO level). Abbreviations: CLDQ-HCV, chronic liver
disease questionnaire-hepatitis C virus version; FACIT-F, functional assessment of
chronic illness therapy-fatigue; PRO, patient-reported outcome; RBV, ribavirin; SF-36,
short-form-36; SOF, sofosbuvir; VEL, velpatasvir; WPAI:SHP, work productivity activity
index:specific health problem.